Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis
- 1 July 2004
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 152 (1-2) , 126-139
- https://doi.org/10.1016/j.jneuroim.2004.03.004
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesAnnals of Neurology, 2001
- VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosisJournal of Neuroimmunology, 2000
- Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissueJournal of Neuroimmunology, 2000
- Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosisJournal of Clinical Investigation, 2000
- Increased numbers of CCR5+ interferon-?- and tumor necrosis factor-?-secreting T lymphocytes in multiple sclerosis patientsAnnals of Neurology, 2000
- Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosisBrain, 1999
- Elevated serum levels of IFN-γ, IL-4 and TNF-α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stageJournal of Neuroimmunology, 1998
- Increased interleukin-6 mRNA expression in blood and cerebrospinal fluid mononuclear cells in multiple sclerosisJournal of Neuroimmunology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- The adhesion molecule and cytokine profile of multiple sclerosis lesionsAnnals of Neurology, 1995